This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Xarelto
  • /
  • Reduced-dosed Rivaroxaban in the Long-term Prevent...
Clinical trial

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (EinsteinChoice)

Read time: 1 mins
Last updated:1st Mar 2014
Identifier: NCT02064439

This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.

Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial.

Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Enrollment: 3396
Study Start Date: March 2014
Study Completion Date: November 2016
Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)

- Experimental:
Arm 1
- Experimental: Arm 2
- Active Comparator: Arm 3

Related journal:
- Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Category Value
Date last updated at source 2017-01-18
Study type(s) Interventional
Expected enrolment 3396
Study start date 2014-03-01
Estimated primary completion date 2016-09-01

View full details